pyrazines has been researched along with Disease Exacerbation in 183 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (1.09) | 18.2507 |
2000's | 65 (35.52) | 29.6817 |
2010's | 100 (54.64) | 24.3611 |
2020's | 16 (8.74) | 2.80 |
Authors | Studies |
---|---|
Gaspar, Z; Kiss-Dala, N; Lakatos, B; Lenart, KS; Petrik, B; Szabo, BG; Szlavik, J; Valyi-Nagy, I | 1 |
Abdul Wahab, S; Adnan, NA; Cheng, JT; Chidambaram, SK; Chow, TS; Chuah, CH; Hor, CP; Ker, HB; Lee, HG; Lee, KS; Mustafa, M; Ng, TK; Nordin, N; Ong, SM; Tee, TY; Zaid, M; Zaidan, NZ | 1 |
Budde, LE; Calvo, R; Champion, R; Coleman, M; Geethakumari, PR; Higgins, K; Lam, S; Levy, MY; Lossos, IS; Ma, S; Patti, C; Strati, P | 1 |
Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B | 1 |
Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL | 1 |
Cai, S; Chew, LA; Jiang, Y; Jin, Y; Khanna, R; Ruan, Y; Wen, C; Xu, Z; Yu, J; Zhong, K | 1 |
Jin, Q; Liu, Z; Luo, Q; Xiong, C; Yan, L; Yu, X; Zhang, Y; Zhao, Q; Zhao, Z | 1 |
Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R | 1 |
Ge, J; Li, H; Liu, Z | 1 |
Amin, EK; Austin, ED; Colglazier, E; Fineman, JR; Hemnes, AR; Leary, PJ; Nawaytou, H; Parker, C; Teitel, D | 1 |
Inoue, KI; Sagawa, T; Takano, H | 1 |
Danilov, AV; Persky, DO | 1 |
Chen, J; Fan, J; Wang, Y; Zhan, Q; Zhang, J; Zhang, L; Zhang, W; Zhao, D | 1 |
Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A | 1 |
Badillo, M; Flowers, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Li, S; Nair, R; Nastoupil, L; Navsaria, L; Ok, CY; Patel, KM; Tang, G; Vega, F; Wang, L; Wang, ML; Yin, CC; Zhang, S | 1 |
Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V | 1 |
Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R | 1 |
Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR | 1 |
Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
Scott, A | 1 |
Asimus, S; Brown, MN; Clarke, GW; Cunoosamy, DM; Ersdal, E; Fagerås, M; Greenaway, S; Hegelund-Myrbäck, T; Jansson, P; Korsback, K; Kristensson, C; Kurian, N; Lundin, S; Make, BJ; Palmér, R; Pardali, K; Patel, NR; Rennard, SI; Siew, L; Taib, Z; Wise, RA | 1 |
Assouline, S; Burke, JM; Chen, R; Essell, J; Patel-Donnelly, D; Sharman, J; Shi, W; Shustov, A; Yang, J; Ye, W | 1 |
Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W | 1 |
Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
Andrews, JA; Cockcroft, BM; Cudkowicz, ME; Hardiman, O; Lee, JH; Malik, FI; Meng, L; Rudnicki, SA; Shefner, JM; Wolff, AA | 1 |
Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S | 1 |
Chen, J; Lin, J; Zeng, Z | 1 |
Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
Cusick, T; Fisher, JE; Glantschnig, H; Kimmel, DB; Langdon, RB; Li, Z; Mu, J; Pennypacker, BL; Scott, KR; Shen, X; Zhang, BB | 1 |
Camidge, DR; Ching, KA; Christensen, JG; Clark, JW; Diamond, JR; Eckhardt, SG; Kanteti, R; Lira, ME; LoRusso, PM; Salgia, R; Schoenmakers, EF; Varella-Garcia, M; Wilner, K; Xu, LG | 1 |
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
Charbonnel, B; Dejager, S; Schweizer, A | 1 |
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L | 1 |
Chen, SJ; Guo, Y; Janin, A; Leboeuf, C; Romero, M; Wang, L; Wu, LL; Xue, K; Yan, ZX; Zhang, QL; Zhao, WL | 1 |
An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D | 1 |
Iyengar, R; Luker, GD; Luker, KE; Moudgil, P; Nyati, S; Rehemtulla, A; Stacer, AC | 1 |
Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A | 1 |
Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
Bryant, J; Clegg, A; Cooper, K; Picot, J | 1 |
Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z | 1 |
Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ | 1 |
Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M | 1 |
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E | 1 |
Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST | 1 |
Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K | 1 |
Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W | 1 |
Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
Chinen, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M; Tatekawa, S; Tsukamoto, T; Yamamoto-Sugitani, M | 1 |
Hobeika, L; Self, SE; Velez, JC | 1 |
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
Li, Y; Qin, H; Tao, Q; Wang, H; Wang, Y; Wang, Z; Xiao, W; Xiong, S; Zhai, Z; Zhang, L | 1 |
Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC | 1 |
Anderson, KC; Bianchini, G; Cottini, F; Hideshima, T; Richardson, PG; Suzuki, R; Tai, YT; Tonon, G | 1 |
Arezzo, J; Bradshaw, KL; Bril, V; Gordon, RJ; Junor, RW; Nash, M; Polydefkis, M; Shaibani, A | 1 |
Adzerikho, I; Channick, R; Chin, KM; Di Scala, L; Frey, A; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Liu, J; McLaughlin, VV; Moiseeva, O; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, V; Zeng, X | 1 |
Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
Bertoglio, J; Bréard, J; Mérino, D; Micheau, O; Ndozangue-Touriguine, O; Sebbagh, M | 1 |
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
Durie, BG | 1 |
Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
Golenkov, AK; Mitina, TA | 1 |
Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS | 1 |
Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH | 1 |
Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK | 1 |
Abdalla, S; Hu, M; Karadimitris, A; Kotsianidis, I; Melo, V; Naresh, K; Rahemtulla, A; Reid, A; Spanoudakis, E; Terpos, E | 1 |
Guerciolini, R; Hsieh, FY; Miwa, G; Pekol, TM; Tengstrand, E | 1 |
Avvisati, G | 1 |
Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J | 1 |
Berenson, JR | 1 |
Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR | 1 |
Lattin, G; Sanders, O; Timpone, V | 1 |
Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT | 1 |
Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB | 1 |
Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM | 1 |
Bode, BW | 1 |
Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM | 1 |
Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P | 1 |
Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L | 1 |
Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y | 1 |
Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD | 1 |
Duong, TQ; Jung, I; Keller, C; Kilcoyne, A; Lin, AL; Morgan, WW; Nelon, LD; Nowak, BM; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Taniguchi, E; Togao, O; Whitney, TG | 1 |
Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
Jagannath, S; Mazumder, A; Vesole, DH | 1 |
Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE | 1 |
Cefalu, WT | 1 |
Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK | 1 |
Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH | 1 |
Kurzrock, R; Subbiah, V; Trent, JC | 1 |
Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F | 1 |
Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P | 1 |
Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A | 1 |
Bagshaw, M; Banwait, R; Ghobrial, IM; Leduc, R; Leleu, X; Roper, N; Weller, E; Xie, W | 1 |
Bladé, J; Hajek, R; Harousseau, JL; Lantz, KC; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
Hayashi, T; Ikeda, H; Imai, K; Ishida, T; Kawakami, K; Kobayashi, T; Nishimura, S; Shinomura, Y; Takahashi, F; Yasui, H | 1 |
Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M | 1 |
Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X | 1 |
Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA | 1 |
Anolik, JH; Barnard, J; Conley, T; Goldman, BI; Ichikawa, HT; Jiang, J; Kirk, CJ; Lee, S; Looney, RJ; Muchamuel, T; Nevarez, S; Owen, T | 1 |
Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T | 1 |
Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C | 1 |
Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH | 1 |
Ge, WP; Liu, N; Lu, D; Ma, CM; Qin, C; Shao, HT; Zhang, LF; Zhang, X | 1 |
Cao, Q; Dudek, AZ; Wang, H | 1 |
Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN | 1 |
Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ | 1 |
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF | 1 |
Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E | 1 |
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
Baas, P; Busacca, S; Cakana, A; Donnellan, P; Fennell, DA; McCaffrey, J; McDowell, C; Meerbeeck, JV; Moulton, B; O'Byrne, KJ; Webb, G | 1 |
Botton, Sd; Boué, F; Bourhis, JH; Crickx, E; Danu, A; Ghez, D; Mariette, X; Miceli, C; Moreau, P; Pasquier, F; Ribrag, V; Wittnebel, S | 1 |
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P | 1 |
Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP | 1 |
Ludwig, H; Sonneveld, P | 1 |
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
Bakris, GL; Flynn, C | 1 |
Faix, JD | 1 |
Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE | 1 |
Kyle, RA; Rajkumar, SV | 1 |
Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
Anderson, KC; Hideshima, T; Rajkumar, SV; Richardson, PG | 1 |
Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W | 1 |
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
Adachi, M; Imai, K; Kawamura, R; Minami, T; Shinomura, Y; Zhang, Y | 1 |
Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J | 1 |
Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T | 1 |
Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG | 1 |
Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA | 1 |
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH | 1 |
Fayad, L; Pro, B; Younes, A | 1 |
Chim, CS; Ooi, GC | 1 |
Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S | 1 |
Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R | 1 |
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
Degendorfer, P; Gomez-Abuin, G; Moore, MJ; Pond, G; Stadler, WM; Winquist, E; Wright, J | 1 |
Anderson, KC | 1 |
Engel, J; Fagbemi, S; Olatosi, B; Onitilo, AA | 1 |
Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
Burns, MJ; Cavallo, F; Elice, F; Esseltine, D; Neuwirth, R; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
Bhandari, M; Jagannath, S | 1 |
Orlowski, RZ; Voorhees, PM | 1 |
Bartlett, NL; Blum, KA; Canellos, GP; Cheson, BD; Johnson, JL; Niedzwiecki, D | 1 |
Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
Faiman, B | 1 |
Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R | 1 |
Anderson, KC; Carrasco, DR; Dranoff, G; Jinushi, M; Munshi, NC; Neuberg, D; Prabhala, RH; Ritz, J; Tai, YT; Vanneman, M | 1 |
Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ | 1 |
Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
Chim, CS; Hwang, YY; Shek, TW | 1 |
Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V | 1 |
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP | 1 |
Stevenson, LW | 1 |
Bourge, R; Carson, P; Feldman, AM; Holubkov, R; Jaski, B; Loftus, S; Soran, O; White, BG; Young, JD | 1 |
Ali, IU; Herbert, BS; Kopelovich, L; Passons, CM; Shay, JW; Wright, AC; Wright, WE | 1 |
Alavijeh, M; Böhme, GA; Boireau, A; Bordier, F; Brealey, C; Briet, D; Canton, T; Debono, MW; Jahn, G; Jimonet, P; Laville, M; Le Guern, S; Mignani, S; Pratt, J; Roberts, S; Roux, M; Stutzmann, JM; Stygall, J; Vuilhorgne, M | 1 |
18 review(s) available for pyrazines and Disease Exacerbation
Article | Year |
---|---|
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Topics: Acetamides; Adult; Anticoagulants; Antihypertensive Agents; Cardiac Catheterization; Disease Progression; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Tolerance; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pulmonary Edema; Pulmonary Veno-Occlusive Disease; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Walk Test | 2019 |
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines | 2020 |
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration | 2021 |
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Intensive Care Units; Pyrazines; SARS-CoV-2; Survival Analysis; Treatment Outcome; Viral Load | 2021 |
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Proteasome inhibition as a novel therapeutic target in human cancer.
Topics: Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2005 |
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
72 trial(s) available for pyrazines and Disease Exacerbation
Article | Year |
---|---|
Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
Topics: Amides; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hypoxia; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome | 2022 |
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2022 |
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome | 2019 |
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Morbidity; Prognosis; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Survival Rate | 2021 |
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis | 2017 |
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Benzamides; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Humans; Lung; Macrophages, Alveolar; Male; Middle Aged; Mitogen-Activated Protein Kinase 14; Proof of Concept Study; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2018 |
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Syk Kinase; Time Factors | 2018 |
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2019 |
A phase III trial of
Topics: Adult; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Muscle Strength; Muscle, Skeletal; Pyrazines; Treatment Outcome | 2019 |
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide | 2013 |
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome | 2014 |
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Topics: Aged; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Pyrazines; Quality of Life; Spiro Compounds; Treatment Outcome | 2015 |
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Aged; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Prodrugs; Pyrazines | 2015 |
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature | 2016 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2008 |
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis | 2010 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome | 2010 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms | 2010 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2010 |
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States | 2012 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence | 2011 |
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Male; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome | 2011 |
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome | 2011 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure | 2012 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2012 |
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
Topics: Aged; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survival Rate | 2012 |
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2013 |
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2004 |
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure | 2005 |
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2005 |
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors | 2005 |
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Survival Analysis; Urologic Neoplasms; Urothelium | 2007 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Topics: Adult; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis; Treatment Failure | 2007 |
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2007 |
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States | 2007 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms | 2008 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
Topics: Cardiotonic Agents; Cause of Death; Chronic Disease; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Retrospective Studies; Substance Withdrawal Syndrome; Survival Rate | 1999 |
93 other study(ies) available for pyrazines and Disease Exacerbation
Article | Year |
---|---|
Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
Topics: Amides; Cohort Studies; COVID-19 Drug Treatment; Disease Progression; Humans; Hungary; Prospective Studies; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pneumonia; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2022 |
Tetramethylpyrazine Reduces Epileptogenesis Progression in Electrical Kindling Models by Modulating Hippocampal Excitatory Neurotransmission.
Topics: Animals; Anticonvulsants; Anxiety; CA1 Region, Hippocampal; Calcium Channel Blockers; Calcium Channels; Convulsants; Disease Progression; Electric Stimulation; Electroshock; Epilepsy, Complex Partial; Excitatory Postsynaptic Potentials; Exploratory Behavior; Ion Transport; Kindling, Neurologic; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Pentylenetetrazole; Pyrazines; Recognition, Psychology; Seizures; Sodium Channels | 2019 |
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation.
Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic | 2020 |
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2020 |
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Progression; Esophageal Neoplasms; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2021 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Substitution; Exome Sequencing; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Sample Size; Treatment Outcome; Withholding Treatment | 2021 |
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine | 2021 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines | 2019 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Progression; Estrogens; Female; Femur; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Ovariectomy; Pyrazines; Rats; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Heterozygote; Humans; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Methionine; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazines; Receptor Protein-Tyrosine Kinases; Sequence Analysis, DNA; Threonine; Treatment Failure; Triazoles | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, T-Cell, Peripheral; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazines | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
NanoLuc reporter for dual luciferase imaging in living animals.
Topics: Animals; Breast Neoplasms; Cell Line; Disease Progression; Female; Heterografts; Imidazoles; Luciferases; Luciferases, Firefly; Luminescent Measurements; Mice; Molecular Imaging; Neoplasm Transplantation; Pyrazines; Signal Transduction; Substrate Specificity; Transfection; Transforming Growth Factor beta | 2013 |
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom | 2014 |
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles | 2014 |
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy | 2014 |
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
CSNK1α1 mediates malignant plasma cell survival.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2015 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Pyrazines | 2015 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Communication; Cell Growth Processes; Cytokines; Disease Progression; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Pyrazines; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2015 |
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2015 |
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Chromosomal Instability; Cluster Analysis; Disease Progression; DNA Damage; DNA Replication; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxidative Stress; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazines; Reactive Oxygen Species; Sulfones | 2015 |
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Cell Membrane Permeability; Colonic Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mitochondria; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines | 2008 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2008 |
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.
Topics: Absorption; Administration, Oral; Alanine Transaminase; Amides; Animals; Arenaviridae Infections; Aspartate Aminotransferases; Cricetinae; Disease Models, Animal; Disease Progression; Female; Hemorrhagic Fevers, Viral; Interferon Type I; Liver Diseases; Mesocricetus; Pichinde virus; Pyrazines; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load | 2008 |
Regulation of multiple myeloma survival and progression by CD1d.
Topics: Antibodies, Monoclonal; Antigens, CD1d; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Aggregation; Cell Survival; Dexamethasone; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Plasma Cells; Pyrazines; Tumor Cells, Cultured | 2009 |
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Topics: Aged; Antineoplastic Agents; Apolipoprotein C-I; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Chromatography, Liquid; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Mass Spectrometry; Middle Aged; Molecular Weight; Multiple Myeloma; Protein Isoforms; Pyrazines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Time Factors | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Worsening low back pain.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Family Practice; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Function Tests; Low Back Pain; Male; Multiple Myeloma; Pain Measurement; Plasmapheresis; Pyrazines; Renal Dialysis; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed | 2009 |
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Functional evaluation of therapeutic response for a mouse model of medulloblastoma.
Topics: Animals; Antineoplastic Agents; Ataxia; Boronic Acids; Bortezomib; Cerebellar Neoplasms; Disease Models, Animal; Disease Progression; Drug Screening Assays, Antitumor; Gait Disorders, Neurologic; Lameness, Animal; Magnetic Resonance Imaging; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; Protease Inhibitors; Psychomotor Performance; Pyrazines; Receptors, Cell Surface | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2010 |
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors | 2010 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome | 2010 |
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies | 2011 |
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease Progression; Drug Therapy, Combination; Graft vs Tumor Effect; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2011 |
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Topics: Animals; Antibody-Producing Cells; Autoantibodies; Boronic Acids; Bortezomib; Disease Progression; Humans; Interferon Type I; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Oligopeptides; Protease Inhibitors; Pyrazines | 2012 |
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Ginsenoside-Rb1 and tetramethylpyrazine phosphate act synergistically to prevent dilated cardiomyopathy in cTnTR141W transgenic mice.
Topics: Animals; Blotting, Western; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; Cardiomyopathy, Dilated; Disease Models, Animal; Disease Progression; Drug Synergism; Drug Therapy, Combination; Echocardiography; Gene Expression Regulation; Ginsenosides; Heparin-binding EGF-like Growth Factor; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Minor clone provides a reservoir for relapse in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53 | 2013 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Salvage Therapy; Stem Cell Transplantation | 2013 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Humans; Multiple Myeloma; Paraproteins; Protease Inhibitors; Pyrazines | 2003 |
Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Topics: Antineoplastic Agents; Boronic Acids; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Humans; Multiple Myeloma; Pyrazines; Treatment Outcome | 2005 |
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; Disease Progression; DNA Damage; Drug Interactions; Humans; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Reactive Oxygen Species; Sulindac; Transplantation, Heterologous | 2005 |
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2005 |
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 2005 |
Bulbar palsy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine | 2005 |
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Approval; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Community experience with bortezomib in patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Community Medicine; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials as Topic; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Predictive Value of Tests; Pyrazines; Time Factors | 2007 |
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cross-Priming; Dendritic Cells; Disease Progression; Histocompatibility Antigens Class I; Humans; Isoantibodies; Ligands; Multiple Myeloma; Prognosis; Pyrazines; Tumor Cells, Cultured | 2008 |
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin | 2008 |
Multiple myeloma with testicular involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome | 2008 |
Inotropic therapy for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Death, Sudden; Disease Progression; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Pyrazines; Quinolines | 1998 |
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Disease Progression; DNA, Complementary; Eflornithine; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Li-Fraumeni Syndrome; Oligodeoxyribonucleotides, Antisense; Point Mutation; Pyrazines; Reverse Transcriptase Inhibitors; Tamoxifen; Telomerase; Thiones; Thiophenes; Transformation, Genetic; Tretinoin | 2001 |
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Disease Progression; Electrophysiology; Electroshock; Excitatory Amino Acid Antagonists; Glutamic Acid; Imidazoles; In Vitro Techniques; Longevity; Mice; Mice, Transgenic; Muscle, Skeletal; Neurons; Patch-Clamp Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Superoxide Dismutase | 2001 |